Table A2.

Demographic Characteristics of the Genomically Matched and Non–Genomically Matched Cohorts of Patients Analyzed for Progression-Free Survival in Figure 4

Characteristic	No. of Patients (%)		P
	Genomic (n = 22)	Nongenomic (n = 54)
Age, years, median (range)	58.5 (17–73)	56 (25–81)	1.00
No. of prior lines of therapy for metastatic disease, mean (range)	2.2 (0–8)	1.8 (0–10)	.43
Sex
Male	7 (32)	34 (37)	.79
Female	15 (68)	20 (63)
No. of alterations, mean (range)	5.5 (2–10)	4.4 (1–10)	.08
No. of actionable alterations, mean (range)	2.5 (0–5)	1.7 (0–6)	.04
Tumor type
Breast triple negative	4 (18)	13 (24)	.76
Breast ER positive/HER2 negative	4 (18)	8 (15)	.74
Lung adenocarcinoma	5 (23)	4 (7)	.11
Lung other	2 (9)	3 (6)	.62
Cholangiocarcinoma	2 (9)	2 (4)	.57
SCC head and neck	0 (0)	6 (11)	.17
Salivary gland	0 (0)	4 (7)	.32
Brain tumor	1 (5)	3 (6)	1.00
Endometrial	0 (0)	3 (6)	.55

NOTE. Continuous data were compared by t test, and categorical data were compared by Fisher’s exact test using GraphPad version 5.0 software.

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; SCC, squamous cell carcinoma.